Figure 3.
Tornado diagram for univariable sensitivity analyses. The grey dotted line represents the incremental cost-effectiveness ratio of US$850.6842 per quality-adjusted life year from the base-case results. ECF/ECX, epirubicin, cisplatin plus fluorouracil or capecitabine; FLOT, fluorouracil, leucovorin, oxaliplatin plus docetaxel; OS, overall survival; PFS, progression-free survival.